Premium Nahrungsergänzungsmittel | artgerecht

Secondary Osteoporosis: Causes, Symptoms and Treatment

Secondary osteoporosis is bone loss caused by an underlying medical condition or medication use. Learn about causes, symptoms, diagnosis, and treatment options.

Regular tips about health Regular tips about health

Things worth knowing about "Secondary Osteoporosis"

Secondary osteoporosis is bone loss caused by an underlying medical condition or medication use. Learn about causes, symptoms, diagnosis, and treatment options.

What Is Secondary Osteoporosis?

Secondary osteoporosis is a form of bone loss in which reduced bone density is not primarily caused by age or hormonal changes, but by an underlying disease or by the long-term use of certain medications. Unlike primary osteoporosis, which mainly affects postmenopausal women, the secondary form can affect men, women, and even younger individuals. Bones become porous, lose structural strength, and the risk of fractures increases significantly.

Causes

Secondary osteoporosis arises from a wide range of underlying conditions or as a side effect of medications. The most common causes include:

Endocrine Disorders

Cushing's syndrome: Excess cortisol production inhibits bone formation.
Hyperthyroidism: An overactive thyroid accelerates bone resorption.
Hyperparathyroidism: Excess parathyroid hormone promotes calcium release from bones.
Type 1 diabetes mellitus: Insulin deficiency impairs bone metabolism.
Hypogonadism: Deficiency of sex hormones (testosterone or estrogen) in both men and women.

Gastrointestinal and Metabolic Disorders

Malabsorption syndromes (e.g., celiac disease, Crohn's disease): Impaired absorption of calcium and vitamin D.
Chronic liver disease: Disruption of vitamin D metabolism.
Chronic kidney disease: Imbalance of calcium-phosphate regulation and vitamin D synthesis.

Rheumatic and Inflammatory Diseases

Rheumatoid arthritis and other chronic inflammatory conditions promote bone resorption through inflammatory mediators.

Medications

Glucocorticoids (e.g., cortisone, prednisone): The most common drug-induced cause; long-term use significantly suppresses bone formation.
Aromatase inhibitors (used in breast cancer therapy) and antiandrogens (used in prostate cancer therapy).
Antiepileptic drugs (e.g., phenytoin, carbamazepine): Accelerate the breakdown of vitamin D.
Proton pump inhibitors with long-term use.
Heparin with long-term use.

Symptoms

Secondary osteoporosis is often asymptomatic for a long time. Symptoms typically appear only when bone density has significantly decreased:

Acute back pain caused by vertebral compression fractures
Loss of height and development of a rounded upper back (kyphosis)
Fractures after minimal trauma (so-called low-energy fractures), especially of the vertebrae, femoral neck, and wrist
Chronic bone pain

Diagnosis

The diagnosis of secondary osteoporosis involves several steps:

Medical history and physical examination: Assessment of pre-existing conditions, medication use, and risk factors.
Bone density measurement (DXA scan): The gold standard for measuring bone mineral density; a T-score of −2.5 or below confirms the diagnosis of osteoporosis.
Laboratory tests: Measurement of calcium, phosphate, vitamin D (25-OH-D), parathyroid hormone, thyroid function, kidney and liver markers, and hormone levels to identify the underlying cause.
X-ray and MRI imaging: Detection of existing fractures or structural bone changes.

Treatment

Treatment of secondary osteoporosis always involves two approaches: addressing the underlying condition and specifically treating bone loss.

Treating the Underlying Condition

The most effective measure is controlling or curing the root cause. If a medication is responsible, dosage reduction or a change of treatment should be considered where clinically possible.

Basic Supportive Therapy

Calcium and vitamin D supplementation: Essential when a deficiency is confirmed.
Exercise and physiotherapy: Strength and balance training to prevent falls.
Smoking cessation and reduction of alcohol intake.

Pharmacological Osteoporosis Therapy

Bisphosphonates (e.g., alendronate, zoledronic acid): Inhibit bone resorption.
Denosumab: A monoclonal antibody that inhibits osteoclast activity and reduces bone breakdown.
Teriparatide / Abaloparatide: Bone-building agents used in severe osteoporosis.
Romosozumab: Binds to sclerostin and stimulates new bone formation.

Prognosis and Prevention

The prognosis depends largely on whether the underlying condition can be successfully treated. Early diagnosis and consistent therapy can halt or slow bone loss and significantly reduce fracture risk. Regular monitoring of bone density is important for evaluating treatment success.

References

Compston J, McClung MR, Leslie WD. Osteoporosis. The Lancet, 393(10169):364-376, 2019. DOI: 10.1016/S0140-6736(18)32112-3
Rosen CJ (ed.). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 8th ed. American Society for Bone and Mineral Research, 2013.
World Health Organization (WHO). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva, 1994.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category